

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): June 27, 2014**

---

**BioCryst Pharmaceuticals, Inc.**  
(Exact Name of Registrant as Specified in Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-23186**  
(Commission  
File Number)

**62-1413174**  
(IRS Employer  
Identification No.)

**4505 Emperor Blvd., Suite 200  
Durham, North Carolina 27703**  
(Address of Principal Executive Offices)

**(919) 859-1302**  
(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 210.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

---

**Item 8.01. Other Events.**

On June 30, 2014, the Agreement (the "Agreement") dated January 3, 2007 between BioCryst Pharmaceuticals, Inc. (the "Company") and the U.S. Department of Health and Human Services ("HHS") expired according to its terms and as a result of completion of the activities funded under the Agreement.

With the expiration of the Agreement and in order to support the existing government inventory, HHS has appropriated \$134,064 to fund continued stability testing of peramivir, which will occur pursuant to a new contract executed on June 27, 2014 between the Company and HHS.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 1, 2014

**BioCryst Pharmaceuticals, Inc.**

By: /s/ Alane Barnes

Alane Barnes

Vice President, General Counsel, and Corporate Secretary